Top

Published in:

01-10-2012 | Substance Use and Related Disorders (JR McKay, Section Editor)

Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders

Authors: Kristen M. Mackowick, Marie-Josee Lynch, Andrea H. Weinberger, Tony P. George

Published in: Current Psychiatry Reports | Issue 5/2012

Abstract

People with mental health and addictive disorders (MHADs) have higher rates of cigarette smoking, and less success in quitting smoking compared with the general population. Moreover, tobacco-related medical illness may be the leading cause of death in the MHAD population. We discuss the scope of this comorbidity, and approaches to the treatment of tobacco dependence in people with MHAD, including schizophrenia, mood disorders, anxiety disorders, and alcohol and substance use disorders. Finally, at the level of health systems, we emphasize the importance of integrated treatment of tobacco dependence in MHADs.

Giovino GA. The tobacco epidemic in the United States. Am J Prev Med. 2007;33:318–26.CrossRef

Center for Disease Control. CDC. Smoking-attributable mortality, years of potential life lost, and productivity losses - United States, 2000–2004. MMWR. 2008;57:1226–8.

Schroeder SA, Warner KE. Don’t forget tobacco. N Engl J Med. 2010;363:201–4.PubMedCrossRef

•• Lasser K, Boyd JW, Woolhandler S, et al. Smoking and mental illness: a population-based prevalence study. J Am Med Assoc. 2000;284:2606–10. An important population-based study of smoking prevalence in persons with and without current and past histories of mental illness based on data from the National Comorbidity Study (NCS), suggesting that persons with mental illness consume a disproportionate amount of cigarettes compared to the general population.CrossRef

Grant BF, Hasin DS, Chou SP, Stinson FS, Dawson DA. Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2004;61:1107–15.PubMedCrossRef

Hitsman B, Moss TG, Montoya ID, George TP. Treatment of tobacco dependence in mental health and addictive disorders. Can J Psychiatry. 2009;54:368–78.PubMed

Tidey JW, Rosenhow DJ, Kaplan GB, Swift RM. Subjective and physiological responses to smoking cues in smokers with schizophrenia. Nicotine Tob Res. 2005;7:421–9.PubMedCrossRef

Brown S, Inskip H, Barraclough B. Causes of excess mortality in schizophrenia. Br J Psychiatry. 2000;177:212–7.PubMedCrossRef

Hennekens CH, Hennekens AR, Hollar D, et al. Schizophrenia and increased risk of cardiovascular disease. Am Heart J. 2005;150:1115–21.PubMedCrossRef

10.

Hser YI, McCarthy WJ, Anglin MD. Tobacco use as a distal predictor of mortality among long-term narcotic addicts. Prev Med. 1994;23:61–9.PubMedCrossRef

11.

Hurt RD, Offord KP, Croghan IT, et al. Mortality following inpatient addictions treatment. role of tobacco use in a community-based cohort. JAMA. 1996;275:1097–103.PubMedCrossRef

12.

Morisano D, Bacher I, Audrain-McGovern J, George TP. Mechanisms underlying the co-morbidity of tobacco use in mental health and addictive disorders. Can J Psychiatry. 2009;54:356–67.PubMed

13.

•• Wing VC, Wass CE, Soh DW, George TP. A review of neurobiological vulnerability factors and treatment implications for comorbid tobacco dependence in schizophrenia. Ann NY Acad Sci. 2012;1248:89–106. A recent review of neurobiological risk factors that predispose to the initiation and maintenance of tobacco dependence in people with schizophrenia.PubMedCrossRef

14.

Lo S, Heishman SJ, Raley H, et al. Tobacco craving in smokers with and without schizophrenia. Schizophr Res. 2011;127:241–5.PubMedCrossRef

15.

Montoya ID, Herbeck DM, Svikis DS, et al. Identification and treatment of patients with nicotine problems in routine clinical psychiatry practice. Am J Addict. 2005;14:441–54.PubMedCrossRef

16.

Berk M, Ng F, Wang WV, et al. 2008: going up in smoke: tobacco smoking is associated with worse treatment outcomes in mania. J Affect Disord. 2008;110:126–34.PubMedCrossRef

17.

Desai HD, Seabolt J, Jann MW. Smoking inpatients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15:469–94.PubMedCrossRef

18.

Weinberger AH, Reutenauer EL, Allen TM, et al. Reliability of the Fagerstrom test for nicotine dependence, Minnesota nicotine withdrawal scale, and Tiffany questionnaire for smoking urges in smokers with and without schizophrenia. Drug Alcohol Depend. 2007;86:278–82.PubMedCrossRef

19.

•• Kelly DL, Raley HG, Lo S, et al. Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia. Schizophr Bull. 2012;38:543–51. A cross-sectional study, which suggested that smokers with schizophrenia compared with non-psychiatric smokers report greater reward perception and social facilitation, poor social pressure to quit smoking and less perception of tobacco-related health risks of smoking.PubMedCrossRef

20.

Ziedonis DM, George TP. Schizophrenia and nicotine use: report of a pilot smoking cessation program and review of neurobiological and clinical issues. Schizophr Bull. 1997;23:247–54.PubMedCrossRef

21.

Addington J, El-Guebaly N, Campbell W, et al. Smoking cessation treatment for patients with schizophrenia. Am J Psychiatry. 1998;155:974–6.PubMed

22.

George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry. 2000;157:1835–42.PubMedCrossRef

23.

Baker A, Richmond R, Haile M, et al. A randomized controlled trial of a smoking cessation intervention among people with a psychotic disorder. Am J Psychiatry. 2006;163:1934–42.PubMedCrossRef

24.

Evins AE, Cather C, Culhane MA, et al. A 12-week double-blind, placebo-controlled study of bupropion SR added to high-dose dual nicotine replacement therapy for smoking cessation or reduction in schizophrenia. J Clin Psychopharmacol. 2007;27:380–6.PubMedCrossRef

25.

George TP, Vessicchio JC, Sacco KA, et al. A placebo-controlled trial of bupropion combined with nicotine patch for smoking cessation in schizophrenia. Biol Psychiatry. 2008;63:1092–6.PubMedCrossRef

26.

Chou KR, Chen R, Lee JF, et al. The effectiveness of nicotine-patch therapy for smoking cessation in patients with schizophrenia. Int J Nurs Stud. 2004;41:321–30.PubMedCrossRef

27.

Evins AE, Mays VK, Rigotti NA, et al. A pilot trial of bupropion added to cognitive behavioral therapy for smoking cessation in schizophrenia. Nicotine Tob Res. 2001;3:397–403.PubMedCrossRef

28.

Evins AE, Cather C, Deckersbach T, et al. A double-blind placebo-controlled trial of bupropion sustained-release for smoking cessation in schizophrenia. J Clin Psychopharmacol. 2005;25:218–25.PubMedCrossRef

29.

Hurt RD, Sachs DPL, Glover ED, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195–201.PubMedCrossRef

30.

George TP, Vessicchio JC, Termine A, et al. A placebo controlled trial of bupropion for smoking cessation in schizophrenia. Biol Psychiatry. 2002;52:53–61.PubMedCrossRef

31.

Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2008;16:CD006103.

32.

Freedman R. Exacerbation of schizophrenia by varenicline. Am J Psychiatry. 2007;164:1269.PubMedCrossRef

33.

Popkin MK. Exacerbation of recurrent depression as a result of treatment with varenicline. Am J Psychiatry. 2008;165:774.PubMedCrossRef

34.

• Williams JM, Anthenelli RM, Morris C, et al. A double-blind, placebo-controlled study evaluating the safety and efficacy of varenicline tartrate for smoking cessation in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2012;73:654–60. The first multi-center double-blind, placebo-controlled evaluation of the safety and efficacy of varenicline for smoking cessation in smokers with schizophrenia and schizoaffective disorder.PubMedCrossRef

35.

Isensee B, Wittchen H, Stein MB, et al. Smoking increases the risk of panic: findings from a prospective community sample. Arch Gen Psychiatry. 2003;60:692–700.PubMedCrossRef

36.

Zvolensky MJ, Forsyth JP, Fuse T, et al. Smoking and non-clinical panic attacks: an initial empirical test of panic-relevant cognitive processes. Cog Behavior Therapy. 2002;31:170–82.CrossRef

37.

Ziedonis DM, Hitsman B, Beckham JC, et al. Tobacco use and cessation in psychiatric disorders: national institute of mental health report. Nicotine Tob Res. 2008;10:1691–715.PubMedCrossRef

38.

Beckham JC, Roodman AA, Shipley RH, et al. Smoking in Vietnam combat veterans with post-traumatic stress disorder. J Trauma Stress. 1995;8:461–72.PubMedCrossRef

39.

Beckham JC, Kirby AC, Feldman ME, et al. Prevalence and correlates of heavy smoking in Vietnam veterans with chronic posttraumatic stress disorder. Addict Behav. 1997;22:637–47.PubMedCrossRef

40.

Op Den Velde W, Aarts PG, Falger PR, et al. Alcohol use, cigarette consumption, and chronic post-traumatic stress disorder. Alcohol Alcohol. 2002;37:355–61.

41.

McFall M, Saxon AJ, Thompson CE, et al. Improving the rates of quitting smoking for veterans with posttraumatic stress disorder. Am J Psychiatry. 2005;162:1311–9.PubMedCrossRef

42.

Hertzberg MA, Moore SD, Feldman ME, et al. A preliminary study of bupropion sustained-release for smoking cessation in patients with chronic post-traumatic stress disorder. J Clin Psychopharmacol. 2001;21:94–8.PubMedCrossRef

43.

•• McFall M, Saxon AJ, Malte CA, et al. Integrating tobacco cessation into mental health care for posttraumatic stress disorder: a randomized clinical trial. JAMA. 2010;304:2485–93. A pivotal multi-center VA Cooperative Study comparing integrated versus separate mental health and tobacco treatment in smokers with post-traumatic stress disorder.PubMedCrossRef

44.

Prochaska JJ. Integrating tobacco treatment into mental health settings. JAMA. 2010;304:2534–5.PubMedCrossRef

45.

Acton GS, Prochaska JJ, Kaplan AA, et al. Depression and stages of change for smoking in psychiatric outpatients. Addict Behav. 2001;26:621–31.PubMedCrossRef

46.

Haug NA, Hall SM, Prochaska JJ, et al. Acceptance of nicotine dependence treatment among currently depressed smokers. Nicotine Tob Res. 2005;7:217–24.PubMedCrossRef

47.

Breslau N, Johnson EO. Predicting smoking cessation and major depression in nicotine-dependent smokers. Am J Public Health. 2000;90:1122–227.PubMedCrossRef

48.

Breslau N, Peterson EL, Schultz LR, et al. Major depression and stages of smoking. a longitudinal investigation. Arch Gen Psychiatry. 1998;55:161–6.PubMedCrossRef

49.

Weinberger AH, George TP, McKee SA. Differences in smoking expectancies in smokers with and without a history of major depression. Addict Behav. 2010;36:434–7.PubMedCrossRef

50.

Thorsteinsson HS, Gillin JC, Patten CA, et al. The effects of transdermal nicotine therapy for smoking cessation on depressive symptoms in patients with major depression. Neuropsychopharmacology. 2001;24:350–8.PubMedCrossRef

51.

Evins AE, Culhane MA, Alpert JE, et al. A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. J Clin Psychopharmcol. 2008;28:660–6.CrossRef

52.

Hall SM, Tsoh JY, Prochaska JJ, et al. Treatment for cigarette smoking among depressed mental health outpatients: a randomized clinical trial. Am J Public Health. 2006;10:1808–14.CrossRef

53.

• MacPherson L, Tull MT, Matusiewicz AK, et al. Randomized controlled trial of behavioral activation smoking cessation treatment for smokers with elevated depressive symptoms. J Consult Clin Psychol. 2010;78:55–61. A well-designed randomized trial of a novel behavioral intervention for smoking cessation in depressed smokers.PubMedCrossRef

54.

Vickers KS, Patten CA, Lewis BA, et al. Feasibility of an exercise counseling intervention for depressed women smokers. Nicotine Tob Res. 2009;8:985–95.CrossRef

55.

Philip NS, Carpenter LL, Tyrka AR, et al. Varenicline augmentation in depressed smokers: an 8-week, open-label study. J Clin Psychiatry. 2009;70:1026–31.PubMedCrossRef

56.

Chengappa KNR, Kambhampati RK, Perkins K, et al. Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. J Clin Psychiatry. 2001;62:503–8.PubMedCrossRef

57.

Trockel M, Burg M, Jaffe A, et al. Smoking behavior postmyocardial infarction among ENRICHD trial participants: cognitive behavior therapy intervention for depression and low perceived social support compared with care as usual. Psychosom Med. 2008;70:875–82.PubMedCrossRef

58.

Weinberger AH, Vessicchio JC, Sacco KC, et al. A preliminary study of sustained-release bupropion for smoking cessation in bipolar disorder. J Clin Psychopharmacol. 2008;28:584–7.PubMedCrossRef

59.

Wu BS, Weinberger AH, Mancuso E, et al. A preliminary feasibility study of varenicline for smoking cessation in bipolar disorder. J Dual Diagnosis. 2012;2:131–2.

60.

Weinberger AH, Sofuoglu M. The impact of cigarette smoking on stimulant addiction. Am J Drug Alcohol Abuse. 2009;35:12–7.PubMedCrossRef

61.

Hays JT, Schroeder DR, Offord KP, et al. Response to nicotine dependence treatment in smokers with current and past alcohol problems. Ann Behav Med. 1999;21:244–50.PubMedCrossRef

62.

• Kalman D, Kahler CW, Garvey AJ, Monti PM. High-dose nicotine patch therapy for smokers with a history of alcohol dependence: 36-week outcomes. J Subst Abuse Treat. 2006;30:213–7. A large study of high- versus low dose transdermal nicotine for smoking cessation in smokers in early alcohol recovery.PubMedCrossRef

63.

• Kalman D, Herz L, Monti P, et al. Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study. Drug Alcohol Depend. 2011;118:111–8. A large study comparing the addition of bupropion SR to transdermal nicotine for smoking cessation in smokers in early alcohol recovery.PubMedCrossRef

64.

Hays JT, Hurt RD, Decker PA, et al. A randomized, controlled trial of bupropion sustained-release for preventing tobacco relapse in recovering alcoholics. Nicotine Tob Res. 2009;11:859–67.PubMedCrossRef

65.

•• Prochaska JJ, Delucchi K, Hall SM. A meta-analysis of smoking cessation interventions with individuals in substance abuse treatment or recovery. J Consult Clin Psychol. 2004;72:1144–56. An outstanding meta-analysis of smoking cessation interventions in smokers with comorbid substance misuse that suggested the safety of concurrent versus sequential interventions for treating comorbid tobacco and other substance abuse.PubMedCrossRef

66.

Joseph AM, Willenbring ML, Nugent SM, Nelson DB. A randomized trial of concurrent versus delayed smoking intervention for patients in alcohol dependence treatment. J Stud Alcohol. 2004;65:681–91.PubMed

67.

Nieva G, Ortega LL, Mondona S. Simultaneous versus delayed treatment of tobacco dependence in alcohol-dependent outpatients. Eur Addict Res. 2010;17:1–9.PubMedCrossRef

68.

Hays JT, Croghan IT, Schroeder DR, et al. Varenicline for tobacco dependence treatment in recovering alcohol-dependent smokers: an open-label pilot study. J Subst Abuse Treat. 2011;41:102–7.CrossRef

69.

McKee SA, Harrison ELR, O’Malley SS, et al. Varenicline reduces alcohol self-administration in heavy-drinking smokers. Biol Psychiatry. 2009;66:185–90.PubMedCrossRef

70.

Nahvi S, Richter K, Li X, et al. Cigarette smoking and interest in quitting in methadone maintenance patients. Addict Behav. 2006;31:2127–34.PubMedCrossRef

71.

Poling J, Rounsaville B, Gonsai K, et al. The safety and efficacy of varenicline in cocaine using smokers maintained on methadone: a pilot study. Am J Addict. 2010;19:401–8.PubMedCrossRef

72.

Okoli CTC, Khara M, Procyshyn RM, et al. Smoking cessation interventions among individuals in methadone maintenance: a brief review. J Subst Abuse Treat. 2010;38:191–9.PubMedCrossRef

73.

Moss TG, Weinberger AH, Vessicchio JC, et al. A tobacco reconceptualization in psychiatry: toward the development of tobacco-free psychiatric facilities. Am J Addict. 2010;19:293–311.PubMed

74.

Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of 10-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res. 2005;80:45–53.PubMedCrossRef

75.

George TP, Ziedonis DM. Addressing tobacco dependence in psychiatric practice: promises and pitfalls. Can J Psychiatry. 2009;54:353–5.PubMed

76.

George TP. Nicotine and tobacco. In: Goldman L, Schaffer A, editors. Cecil textbook of medicine. 24th ed. New York, NY: Elsevier; 2011. p. 2672.

Title: Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders
Authors: Kristen M. Mackowick
Marie-Josee Lynch
Andrea H. Weinberger
Tony P. George
Publication date: 01-10-2012
Publisher: Current Science Inc.
Published in: Current Psychiatry Reports / Issue 5/2012
Print ISSN: 1523-3812
Electronic ISSN: 1535-1645
DOI: https://doi.org/10.1007/s11920-012-0299-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Treatment of Tobacco Dependence in People With Mental Health and Addictive Disorders

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2012

Personalized Treatment of Alcohol Dependence

Management of Post-Traumatic Nightmares: A Review of Pharmacologic and Nonpharmacologic Treatments Since 2010

Emerging Association Between Addictive Gaming and Attention-Deficit/Hyperactivity Disorder

Neuroimaging of Attention-Deficit/Hyperactivity Disorder: Current Neuroscience-Informed Perspectives for Clinicians

Attention-Deficit/Hyperactivity Disorder Genomics: Update for Clinicians

Emerging Support for a Role of Exercise in Attention-Deficit/Hyperactivity Disorder Intervention Planning